Defining key deprescribing measures from electronic health data: A multisite data harmonization project.

Dublin S, Albertson-Junkans L, Pham Nguyen TP, Pavon JM, Hastings SN, Maciejewski ML, Willis A, Zepel L, Hennessy S, Albers KB, Mowery D, Clark AG, Thomas S, Steinman MA, Boyd CM, Bayliss EA. Defining key deprescribing measures from electronic health data: A multisite data harmonization project. Journal of the American Geriatrics Society. 2024 Nov 28.

Related HSR&D Project(s)

• RCS 10-391 – Research Career Scientist

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Stopping or reducing risky or unneeded medications ("deprescribing") could improve older adults'' health. Electronic health data can support observational and intervention studies of deprescribing, but there are no standardized measures for key variables, and healthcare systems have differing data types and availability. We developed definitions for chronic medication use and discontinuation based on electronic health data and applied them in a case study of benzodiazepines and Z-drugs in five diverse US healthcare systems. METHODS: We conducted a retrospective cohort study of adults age 65+ from 2017 to 2019 with chronic benzodiazepine or Z-drug use. We determined whether sites had access to medication orders and/or dispensings. We developed definitions for chronic use and discontinuation using both data types. Discontinuation definitions were based on (1) gaps in medication availability during follow-up or (2) not having medication available at a fixed time point. We examined the impact of varying the gap length and requiring a 30-day period without orders/dispensings ("halo") around the fixed time point. We compared results derived from orders versus dispensings at one site. RESULTS: Approximately 1.6%-2.6% of older adults had chronic benzodiazepine/Z-drug use (total N? = 6775, ranging from 431 to 2122 across sites). Depending on the definition and site, the proportion discontinuing use during 12?months ranged from 6% to 49%. Requiring a longer gap or a 30-day "halo" resulted in lower estimates. At one site, only 56% of those with chronic use defined from orders also qualified based on dispensings, and the discontinuation rate at 180?days was 20% from orders versus 32% from dispensings. CONCLUSIONS: Requiring a gap of = 90?days or a "halo" around a time point may more accurately capture discontinuation than using a shorter gap or no halo. Orders data underestimate discontinuation compared to dispensings. Work is needed to adapt these definitions for other drug classes and settings.